SEOUL, Aug. 18 (Korea Bizwire) – SK Biopharmaceuticals Co., a pharmaceutical affiliate of South Korea’s SK Group, said Friday it has reached a license and commercialization deal with the Middle East unit of British drugmaker Hikma Pharmaceuticals Plc. Under the deal, Hikma MENA FZE is granted an exclusive license to develop and commercialize the Korean [...]
SEOUL, June 30 (Korea Bizwire) — SK Biopharmaceuticals announced on Friday its acquisition of 40 million shares of ProteoVant Sciences, a US-based research and development company, for 62 billion won (US$47 million). The purchase includes all shares held by Roivant Science, ProteoVant’s largest shareholder with a 60% stake. SK holdings, the parent company of SK [...]
SEOUL, Dec. 14 (Korea Bizwire) — SK Biopharmaceuticals Co., a pharmaceutical affiliate of South Korea’s SK Group, said Wednesday it aims to transform into a global health care solutions provider based on the successful rollout of its anti-epilepsy treatment. “SK Biopharm is to become a world-leading health care solutions company that provides comprehensive services to [...]
SEOUL, July 14 (Korea Bizwire) — SK Biopharmaceuticals Co., a biopharmaceutical affiliate of South Korea’s SK Group, said Thursday it has signed a deal with Eurofarma Laboratorios SA to develop and commercialize its anti-epileptic drug Cenobamate in 17 Latin American countries. Under the deal, SK Biopharmaceuticals will receive an upfront payment of US$62 million and [...]
SEOUL, Nov. 25 (Korea Bizwire) — South Korean drug firm SK Biopharmaceuticals Co. is expected to raise at least 5 trillion won (US$4.25 billion) through a planned share sale, analysts said Monday. The company said Friday that XCOPRI, or cenobamate, has won approval from the U.S. Food and Drug Administration (FDA) for the treatment of [...]
SEOUL, Nov. 22 (Korea Bizwire) — SK Biopharmaceuticals Co., a biopharmaceutical affiliate of South Korea’s SK Group, said Friday its anti-epileptic drug has won approval from the U.S. Food and Drug Administration (FDA). SK Biopharmaceuticals said the FDA granted approval of XCOPRI, or cenobamate tablets, for the treatment of partial-onset seizures in adults. This is [...]